Therapies

Docetaxel

Taxotere

This post is under:

Oncofocus Test Kit
includes suggestions for Docetaxel

Oncofocus is the world’s most comprehensive precision oncology test that precisely identifies the right drug for your cancer thereby increasing your chances of successful treatment.

Discover Oncofocus Today Do you want to order now? Request a test.

SUMMARY

Company: Rhone Poulenc Rorer
Approval Status:  FDA Approved May 1996
Specific Treatments: Breast Cancer
Drug: Docetaxel 

 

GENERAL INFORMATION

Taxotere has been approved as a treatment for subjects who have locally advanced or metastatic (spreading) Breast Cancer, which has progressed during anthracycline-based therapy or has relapsed during anthracycline-based adjuvant therapy. Approximately two out of three breast cancer subjects treated with chemotherapy in the United States receive anthracyclines at some point in the treatment of their disease.

Anthracycline-based chemotherapy is commonly used by oncologists as initial therapy for metastatic disease and as adjuvant chemotherapy administered in conjunction with surgery to prevent disease recurrence. In subjects with advanced disease, their cancer will eventually become resistant and stop responding to the treatment.

Unlike other chemotherapeutic agents, Taxotere can be administered outside the hospital.

The approved outpatient regimen for Taxotere is 60 to 100 mg/m2 administered intravenously for one hour every three weeks. Other currently used chemotherapy agents may require hospitalization due to much longer infusion times.

As of June 1998, Taxotere is approved for first-line treatment of metastatic Breast Cancer in subjects whose disease has recurred despite adjuvant therapy.

 

CLINICAL RESULTS

In worldwide phase II clinical trials, Taxotere demonstrated the highest tumor response rates ever reported for a single agent in this subject population.

Taxotere has been studied extensively in clinical trials involving thousands of subjects worldwide, including the United States, Canada, Japan, and Europe. Additional clinical trials are ongoing to investigate the potential use of Taxotere to treat other tumor types.

 

SIDE EFFECTS

Side effects have been shown to be predictable and manageable. They include hair loss, reduced white blood cell count, skin rash, fluid retention, hypersensitivity, nausea, and diarrhea.

 

MECHANISM OF ACTION

Taxotere is a new chemical entity that inhibits cancer cell growth, which depends on the formation of an internal cellular skeleton made up of elements called microtubules. During the cell development cycle, microtubules first assemble and then disassemble, permitting cancer cells to divide and thus allow tumor growth. Taxotere essentially freezes the cancer cell’s internal skeleton by promoting the assembly and blocking the disassembly of microtubules. This action prohibits cancer cell division, which causes cell death.

Source: centerwatch

SUMMARY

Company: Rhone Poulenc Rorer
Approval Status:  FDA Approved May 1996
Specific Treatments: Breast Cancer
Drug: Docetaxel 

 

GENERAL INFORMATION

Taxotere has been approved as a treatment for subjects who have locally advanced or metastatic (spreading) breast cancer, which has progressed during anthracycline-based therapy or has relapsed during anthracycline-based adjuvant therapy. Approximately two out of three breast cancer subjects treated with chemotherapy in the United States receive anthracyclines at some point in the treatment of their disease.

Anthracycline-based chemotherapy is commonly used by oncologists as initial therapy for metastatic disease and as adjuvant chemotherapy administered in conjunction with surgery to prevent disease recurrence. In subjects with advanced disease, their cancer will eventually become resistant and stop responding to the treatment.

Unlike other chemotherapeutic agents, Taxotere can be administered outside the hospital.

The approved outpatient regimen for Taxotere is 60 to 100 mg/m2 administered intravenously for one hour every three weeks. Other currently used chemotherapy agents may require hospitalization due to much longer infusion times.

As of June 1998, Taxotere is approved for first-line treatment of metastatic breast cancer in subjects whose disease has recurred despite adjuvant therapy.

 

CLINICAL RESULTS

In worldwide phase II clinical trials, Taxotere demonstrated the highest tumor response rates ever reported for a single agent in this subject population.

Taxotere has been studied extensively in clinical trials involving thousands of subjects worldwide, including the United States, Canada, Japan, and Europe. Additional clinical trials are ongoing to investigate the potential use of Taxotere to treat other tumor types.

 

SIDE EFFECTS

Side effects have been shown to be predictable and manageable. They include hair loss, reduced white blood cell count, skin rash, fluid retention, hypersensitivity, nausea, and diarrhea.

 

MECHANISM OF ACTION

Taxotere is a new chemical entity that inhibits cancer cell growth, which depends on the formation of an internal cellular skeleton made up of elements called microtubules. During the cell development cycle, microtubules first assemble and then disassemble, permitting cancer cells to divide and thus allow tumor growth. Taxotere essentially freezes the cancer cell’s internal skeleton by promoting the assembly and blocking the disassembly of microtubules. This action prohibits cancer cell division, which causes cell death.